BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2058 related articles for article (PubMed ID: 29128059)

  • 1. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Cholesterol in the Pathogenesis of NASH.
    Ioannou GN
    Trends Endocrinol Metab; 2016 Feb; 27(2):84-95. PubMed ID: 26703097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of nonalcoholic steatohepatitis.
    Liu W; Baker RD; Bhatia T; Zhu L; Baker SS
    Cell Mol Life Sci; 2016 May; 73(10):1969-87. PubMed ID: 26894897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Gentilini A; Caligiuri A; Provenzano A; Marra F
    Curr Mol Med; 2016; 16(8):710-720. PubMed ID: 27774883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
    Liu W; Baker SS; Baker RD; Zhu L
    Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers in nonalcoholic steatohepatitis.
    Armutcu F; Akyol S; Ucar F; Erdogan S; Akyol O
    Adv Clin Chem; 2013; 61():67-125. PubMed ID: 24015600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells.
    Magee N; Zou A; Zhang Y
    Biomed Res Int; 2016; 2016():5170402. PubMed ID: 27822476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
    Handa P; Vemulakonda A; Kowdley KV; Uribe M; Méndez-Sánchez N
    World J Gastroenterol; 2016 Aug; 22(31):6965-71. PubMed ID: 27610009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
    Parafati M; Kirby RJ; Khorasanizadeh S; Rastinejad F; Malany S
    Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways of nonalcoholic fatty liver disease development and progression.
    Bessone F; Razori MV; Roma MG
    Cell Mol Life Sci; 2019 Jan; 76(1):99-128. PubMed ID: 30343320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Arab JP; Arrese M; Trauner M
    Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vitamin E in nonalcoholic fatty liver disease.
    Nagashimada M; Ota T
    IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.